Issued 2026-08-13 at $14.39 · now $14.85 (2026-08-13, +3.2% since)
Based on its own history, a month from the 2026-08-13 close, BHVN has typically landed between $10.68 and $20.05 — a range of −25.8% to +39.3% from the issuance price $14.39.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
954 overlapping 1 month windows · 2022-09-23 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($14.39) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where BHVN has typically landed a month from the 2026-08-13 close of $14.39 — the range is history, not a prediction.
- now $14.85 (+3.2%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $14.55 (+1.1%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $12.59–$16.51
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $10.68–$20.05
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2025-10-15 | −53.5% | −55.1% | +4.3% |
| 2025-10-14 | −52.3% | −53.2% | +8.7% |
| 2025-10-09 | −52.1% | −52.1% | +5.1% |
| 3 best | |||
| 2022-09-30 | +163.0% | +0.0% | +163.0% |
| 2022-10-03 | +139.4% | +0.0% | +139.4% |
| 2022-09-29 | +126.8% | −6.8% | +126.8% |
954 overlapping windows · 2022-09-23 – 2026-08-13 · not cherry-picked
Pending catalysts
- September 2026 — Trial primary completion: Phase 2 primary completion: Taldefgrobep Alfa in Adults With Overweight and Obesity (source, as of 2026-08-14)
- October 2026 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (source, as of 2026-08-14)
- December 2026 — Trial primary completion: Phase 2 primary completion: Long-term Safety and Tolerability of BHV-7000 (source, as of 2026-08-14)
- December 2026 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy (source, as of 2026-08-14)
- August 2027 — Trial primary completion: Phase 2/Phase PHASE3 primary completion: A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease (source, as of 2026-08-14)
- January 2028 — Trial primary completion: Phase 3 primary completion: Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease (source, as of 2026-08-14)
- February 2028 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~4 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.